BHS guidelines for the treatment of marginal zone lymphomas. by BRON, D. et al.
1Belgian Journal of Hematology   Volume 5, Issue 1, March 2014
12
1Department of Haematology, Institut Jules Bordet (ULB), Brussels, Belgium 2Department of Haematology, Cliniques Universitaires St Luc, Brussels, 
Belgium 3Department of Haematology, Hôpital de Jolimont, Haine St Paul, Belgium 4Department of Haematology, Universitair Ziekenhuis, Gent, 
Belgium 5Department of Haematology, Universitair Ziekenhuis, Antwerp, Belgium 6Department of Haematology, Centre Hospitalier Universitaire, 
Liège, Belgium 7Department of Haematology, AZ St Jan, Brugge, Belgium 8Department of Haematology, Gasthuisberg, Leuven, Belgium.
Please send all correspondence to: D. Bron, MD, PhD,  Institut Jules Bordet, Department of Haematology, 1 Rue Héger Bordet, 1000 Brussels, 
Belgium, tel: +32 2 541 32 32, email: dbron@ulb.ac.be.   
Conflict of interest: The authors have nothing to disclose and indicate no potential conflict of interest.
Keywords: helicobacter pylori, marginal zone lymphoma, non-Hodgkin’s lymphoma, splenic marginal zone lymphoma.
BHS guidelines for the treatment of 
marginal zone lymphomas 
D. Bron, MD, PhD1,  E. Van den Neste, MD, PhD2,  A. Kentos, MD3,  F. Offner, MD, PhD4,  W. Schroyens, 
MD, PhD5,  C. Bonnet, MD, PhD6,  A. Van Hoof, MD, PhD7,  G. Verhoef MD, PhD8, A. Janssens, MD8
Marginal zone lymphomas are a heterogeneous subtype of indolent B-non-Hodgkin Lymphoma that 
includes three distinct diseases: Extranodal mucosa associated lymphoid tissue lymphoma, nodal 
marginal zone lymphoma and splenic marginal zone lymphoma lymphocytes +/- villous lymphocytes. 
The different diagnosis, work up and treatment options are discussed in these guidelines.
(Belg J Hematol 2014;5(1):12-21)
Introduction
Marginal zone lymphoma (MZL) is an indolent B-non-
Hodgkin lymphoma (NHL) that includes three distinct 
diseases, all arising from post-germinal centre marginal 
zone B cells and sharing a similar immunophenotype 
(CD20+, CD19+, CD22+, CD 27+, FMC7+, CD5-, 
CD10-, κ or λ+):1
1.  Extranodal MZL of Mucosa Associated Lymphoid 
Tissue (MALT) type (including gastric and non-
gastric MALT lymphomas)
2. Nodal MZL (with or without circulating B cells)
3. Splenic MZL (with or without villous lymphocytes)
MZL (including MALT) represent 11% of all non-
Hodgkin’s lymphomas.2 The Matutes score is generally 
very low  (below three).
This topic review will separately discuss diagnosis, 
work up and treatment of gastric and non-gastric MALT 
lymphoma’s, nodal MZL and splenic MZL. These guide-
lines include the recently published ESMO consensus 
conference on malignant lymphoma.3 
Gastric MZL of MALT type 
Incidence
Mucosa associated lymphoid tissue (MALT) lymphomas 
represent 7-8% of all non-Hodgkin’s lymphomas and 
can arise at any extranodal site; however, at least one-
third of them present as a primary gastric lymphoma.2,4,5 
Its development is often associated with Helicobacter 
Pylori (HP) infection. Median age is 60 years old with 
a male predominance.
Diagnosis
The most common presenting symptoms of gastric 
MALT lymphoma are non-specific upper gastrointesti-
nal (GI) complaints that often lead to an endoscopy 
usually revealing non-specific gastritis or peptic ulcer 
with mass lesions being unusual.
Diagnosis is based on the histopathological evaluation 
of the gastric biopsies. If the presence of active HP 
infection is not demonstrated by histology (sensitivity 
> 80%), it must be ruled out by a urea breath test and/
or a stool antigen test.
In addition to routine histology and immunohistochem-
istry, fluorescence in situ hybridisation (FISH) analysis 
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(or polymerase chain reaction (PCR)) for detection of 
t(11;18) may be useful for identifying patients that are 
unlikely to respond to antibiotic therapy and with a 
possible histologic transformation.2 Other chromosomal 





•	 	Complaints	 (night	 sweats,	 weight	 loss,	 pruritus,	 
fever, diarrhoea, abdominal pain, etc.)
•	 	Physical	 examination	 (LN,	mucosa,	 other	EN	 in-
volvement, spleen, skin, etc.)
•	 Performance	status
•	 	Lab	 tests:	 CBC	with	 diff	 and	 phenotype,	 biology	
with LDH, uric acid, ESR, ANA, RF, β2 microglob-





optional (FISH or PCR for t(11;18))
•	 	Chest	X-ray,	CT	scan	or	MRI,	endoscopy	if	indicated	
(endoscopic ultrasound is then preferred)
Staging and risk assessment
The initial staging procedures should include a gastro-
duodenal endoscopy with multiple biopsies taken from 
each region of the stomach and from any abnormal-
appearing site. Endoscopic ultrasound is recommended 
to evaluate gastric wall infiltration and regional lymph 
nodes, also useful before irradiation.
PET/CT has limited value in low grade lymphomas such 
as MZL and is not recommended unless a histologic 
transformation is suspected. 
This type of lymphoma has an unusual clinical course, 
the international prognostic index (IPI) is not correlated 
with overall survival (OS) and a specific staging system 
is now recommended by the National Cancer Compre-
hensive Network (NCCN) guidelines (Table 1).
Treatment plan
Localised HP-positive gastric MALT lymphoma (Lugano 
staging system: stage IE-IIE)
Localised HP-positive gastric MALT lymphoma often 
responds to eradication of HP infection with antibiotics 
+ proton-pump inhibitor as the sole initial treatment.7 
Any of the highly effective anti-HP antibiotic regimens 
proposed can be used (Table 3). In case of unsuccessful 
HP eradication (breath test at four-six weeks after treat-
ment, two weeks without PPI), a second-line therapy 
should be attempted with alternative triple- or quadru-
ple-therapy regimens of proton-pump inhibitor plus 
antibiotics.8,9 HP eradication can induce lymphoma 
regression and long-term clinical disease control in 50-
80% of patients.10 The length of time necessary to obtain 
a remission varies from two months to > twelve months 
(Med = 5 Mos). It is reasonable to wait at least twelve 
months before starting another treatment in patients 
who achieve a clinical and endoscopic remission together 
with eradication of HP, albeit having persistent (residual) 
lymphoma at the histological level. Several studies of 
post-antibiotic molecular follow-up have shown the 
persistence of monoclonal B cells after histological 
regression of the lymphoma. In these cases, watchful 
Figure 1. B follicle scheme adapted from C. De Wolf-Peeters.45
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- Nodal monocytoid MZL
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waiting is recommended, while active anticancer treat-
ment should be reserved for persistently symptomatic 
or progressive disease.11 Level of evidence: III – recom-
mendation A.
Localised HP-negative gastric MALT lymphomas who 
fail HP eradication therapy (Lugano staging system: 
stage IE-IIE)
For localised HP-negative gastric MALT lymphomas 
who fail HP eradication therapy, irradiation or systemic 
chemo- or immunotherapies should be applied depend-
ing on the stage of disease; surgery has not been shown 
to achieve superior results in comparison with more 
conservative approaches in various trials.
Gastric MALT lymphomas are usually localised and 
excellent disease control using radiation therapy alone 
has been reported by several institutions supporting the 
use of modest-dose involved-field radiotherapy (30 Gy 
radiation to the stomach and perigastric nodes given in 
four weeks).12  Level of evidence: IV –  recommendation B.
Patients with systemic disease (Lugano staging system: 
stage III-IV)  
Patients with systemic disease should be considered for 
systemic chemotherapy and/or immunotherapy with 
anti-CD20 monoclonal antibodies (rituximab 375mg/
m²/week x 4).13 Only a few compounds and regimens 
have been tested specifically in MALT lymphomas. 
Oral alkylating agents (either cyclophosphamide [100mg/ 
d x 6-12 months] or chlorambucil (Chl) [6mg/m²/d x 
6-12 months]) or purine analogues (fludarabine [30mg/
m²/d x 3 – q28d x 6 months]) can result in a high rate 
of disease control. The activity of the anti-CD20 mono-
clonal antibody rituximab has also been shown a in 
a randomised phase III study. Rituximab combined 
with Chl is now proven to be superior to Chl alone in 
PFS (68% vs. 50% at five years) but not in OS.14 The 
major toxicities of rituximab include infusion reactions 
(fevers, rigors and hypotension) and infections related 
to immunosuppression. Rituximab also imposes a risk 
of hepatitis B reactivation among patients positive for 
hepatitis B surface antigen (HBsAg) or antibodies against 
hepatitis B core antigen (anti-HBc). There is no clear 
evidence in the published literature to recommend any 
specific drug or regimen; it should, however, be men-
tioned that treatment with purine analogues might be 
associated with an increased risk of secondary myelodys-
plasia. Anthracycline-containing regimens are not recom-
Table 1. National Cancer Comprehensive Network guidelines for gastrointestinal lymphomas according 
to the Lugano staging system.





system adapted for 
gastric lymphoma 
Tumour extension 
Stage IE Confined to GI tract 
I
E1
 = mucosa, submucosa I
E
 T1 N0 M0 Mucosa, submucosa 
I
E2
  = muscularis propria, serosa I
E
 T2 N0 M0 Muscularis propria 
I
E
 T3 N0 M0 serosa 
Stage IIE Extending into abdomen 
II
E
1  = local nodal involvement II
E
T1-3 N1 M0 Perigastric lymph nodes 
II
E
2   = distant nodal involvement II
E
T1-3 N2 M0 More distant regional lymph nodes 
Stage IIE Penetration of serosa to involve 
adjacent organs or tissues 
II
E
T4 N0 M0 Invasion of adjacent structures 
Stage III-IV Disseminated extranodal 





 T1-4 N3M0 Lymph nodes on both sides of 
the diaphragm / distant metastases 
(e.g. bone marrow or additional 
extranodal sites 
IV T1-4 N0 M3 
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mended and should be reserved for the few patients 
with a high tumour burden or transforming histologies. 
None of the approaches for systemic disease has shown 
a benefit in survival but median OS is excellent (20 
years).12 Level of evidence: III – recommendation B.
Lymphoma with diffuse large cell infiltration should be 
treated according to recommendations for diffuse large 
cell lymphomas.15
Response evaluation and follow-up
Histological evaluation of repeated biopsies remains an 
essential follow-up procedure. Unfortunately, the inter-
pretation of the lymphoid infiltrate in post-treatment gas-
tric biopsies can be very difficult and there are no uni-
form criteria for the definition of histological remission. 
A surveillance breath test or stool antigen test should 
be performed at least four weeks after the antibiotic 
treatment to document HP eradication (PPI must be 
stopped at least one week before HP testing). Then, a 
strict endoscopic follow-up is recommended, with mul-
tiple biopsies taken two–three months after treatment, 
and subsequently, at least twice a year for two years, to 
monitor histological regression of the lymphoma. 
Gastric MALT lymphomas have limited tendency to 
distant spreading and to histological transformation. 
Transient histological local relapses are possible but 
tend to be self-limiting especially in the absence of HP 
reinfection. In the case of persistent but stable residual 
disease or histological relapse (without distant dissem-
ination and/or gross endoscopic tumour) a watch-and-
wait policy appears to be safe. Nevertheless, long-term 
careful endoscopic and systemic (blood counts and 
minimal adequate radiological or ultrasound examina-
tions) follow-up annually is recommended for all patients. 
Indeed, patients with gastric MALT lymphoma have 
a sixfold higher risk than the general population of de-
veloping a gastric adenocarcinoma.16
Non-Gastric Extranodal MZL of MALT type 
Incidence
Mucosa associated lymphoid tissue (MALT) lymphomas 
arise in a number of epithelial tissues, including the 
stomach but also salivary gland, lung, small bowel and 
colon, thyroid, skin, breast, ocular adnexa, etc.17 Non-
gastric extranodal MZL may also be associated with 
chronic immune stimulation by infectious agents (HP or 
H. Heilmanni, Borrelia Burgdorferi, Chlamydia Psittaci, 
Campylobacter Jejuni, HCV) or autoimmune disorders 
(Sjögren disease, Hashimoto thyroiditis, Crohn disease, 
Rheumatoid Arthritis, etc.).4,18,19
Diagnosis
The most common presenting symptoms of non-gastric 
MALT lymphoma are non-specific complaints (diar-
rhoea, abdominal pain, cough, skin nodules or any other 
clinical symptom related to the involved organ). Median 
age at diagnosis is 60 years old. 
Diagnosis is based on the histopathological evaluation 
of the biopsies. For the GI localisations, presence of 
active HP infection – not demonstrated by histology – 
must be ruled out by urea breath test and/or stool antigen 
test. Campylobacter Jejuni in the small intestine can be 
detected by PCR in the setting of IPSID.
Viral and bacterial serologies are required to exclude 
active chronic bacterial stimulation (Borrelia, Chlamy-
dia, Campylobacter and HCV). However, serologies are 
usually negative and molecular techniques should be 
performed to exclude these pathogens. The majority 
of patients present with localised stage I or II disease. 
Twenty five percent have bone marrow involvement. 
Thirty percent show a monoclonal gammopathy.20,21
A special issue is the primary cutaneous MZL some-
times associated with Borrelia Burgdorferi infections.22 
The lesion is usually a deep red infiltrated nodule sur-
rounded by diffuse erythema localised to the extremities 
or the trunk, rarely disseminated.
Table 2. Differential Diagnosis of B- Lymphocytosis.
CLL HCL PLL F NHL MCL MZL
↑↑ lympho ++ + +++ + + +++ 
Spleen +/- ++ ++ +/- +/- +++ 
CD19 + + ++ ++ ++ ++ ++ 
CD5 ++ - - - ++ - 
CD23 + - - - - - 
CD25 +/- ++ - - - - 
CD11c +/- ++ - - - - 
FMC7 - - ++ + + + 
CD103 - + - - - +/-






fever, cough, diarrhoea, abdominal pain, etc.)
•	 	Physical	examination	(LN,	mucosa,	other	EN	involve-
ment, spleen, skin, etc.)
•	 Performance	status
•	 	Lab	tests:	CBC	with	diff	and	phenotype,	biology	with	
LDH, uric acid, ESR, ANA, RF, β2 microglobulin, 
viral serologies (HCV, HBV, HIV) and bacterial serol-
ogies (Borrelia, HP, Chlamydia, Campylobacter)
•	 	Helicobacter	P	on	histology,	urea	breath	test,	stool	
antigen test, HP serology
•	 	BM	biopsy	with	phenotype.	Cytogenetic	analysis	is	
optional (FISH or PCR for t(11;18))
•	 	Chest	X-ray,	CT	scan	or	MRI,	endoscopy	if	indicated	
(endoscopic ultrasound is then preferred)
Staging and risk assessment
The initial staging procedures should include multiple 
biopsies taken from each abnormal-appearing site. The 
value of PET scan is controversial and has little clinical 
value. Patients should be tested for hepatitis B prior to 
rituximab therapy.
Treatment plan (Table 3)
HP-positive localised MALT lymphoma
In HP-positive localised MALT lymphoma, eradication 
of HP with antibiotics should be employed (see details 
in gastric MALT lymphoma) but unlike in gastric lym-
phomas, the benefit of eradication therapy for non-
gastric MALT is unproven.23
Limited (stage I-II) disease
Limited stage extranodal MALT includes those patients 
with involvement of a single extralymphatic site (IE) or 
a lymph node extending into a contiguous extralym-
phatic organ or tissue (IIE). Surgery is typically used 
for diagnostic purpose only but may play a role in the 
treatment of tumours in areas not conducive to radia-
tion therapy (i.e. lung). The addition of adjuvant che-
motherapy or antibiotic therapy has not demonstrated 
improved disease-free or OS.24  There are occasional 
patients with stage I disease who are not candidates for 
radiation therapy and may be initially observed closely.25
Locoregional radiotherapy (RT) with 25 to 30 Gy is the 
principal therapy for most cases of limited stage extrano-
dal MALT. This lymphoma is very sensitive to radiation 
and doses should not exceed 30 Gy. With this approach, 
complete responses are seen in >90% of cases.26,27  






- PPI triple therapy:
- Omeprazole 20 mg +
- Clarithromycin 500 x2/d +
- Amoxicillin 1 g x2/d for 14d 
Localised diseases
• Surgery if not gastric
• Local radiotherapy if indicated
•  Single agent: 
- Rituximab: 375 mg/m²/wk x 4 
- Chlorambucil: 16 mg/m²/d,  5d/m x 6mo or 6 mg/m²/d x 6-12mo 
- Cyclophosphamide: 10 mg/m²/d x 6-12 mo
Chlamydia Psittaci 
- Doxycycline 100 mg/J  3 wks
Disseminated diseases 
•  Single agent: 
- Rituximab: 375 mg/m²/wk x 4 +/- 
- Chlorambucil: 16 mg/m²/d,  5d/m x 6mo or 6 mg/m²/d x 6-12mo 
- CPA: 10 mg/m²/d x 6-12 mo 
- Fludarabine:  30mg/m²/mo x 6 mo
Borrelia Burgdorferi
- Doxycycline 100 mg/J or amoxicillin, 3 wks
•  Polychemotherapy  
R-CHOP every 3 wk for 6-8 cycles 
R-FC every 4 wks for 6 cycles
Campylobacter Jejuni 
-Erythromycin or fluoroquinolone 
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A prospective phase II study evaluated the use of RT in 
patients with previously untreated stage IEA non-gastric 
MALT lymphoma (24 orbital, four thyroid, four salivary 
gland and five others). Complete remission or complete 
remission/unconfirmed was achieved in 92% of patients. 
Three-year OS, PFS, and local control rates were 100, 
92 and 97%, respectively. 
In a retrospective study of 70 patients with stage IE or 
IIE MALT lymphoma, including some patients with 
gastric MALT, mostly treated with involved-field RT 
alone (25 to 35 Gy) reported five-year disease-free (DFS) 
and OS of 76% and 96%. 
Relapses are most commonly seen in the contralateral 
paired organ or in a distant site.
Because of the risk of the ocular structures to radiation, 
doses of 25 to 30 Gy are used for ocular MALT with ex-
cellent results. With recurrent disease or advanced dis-
ease, lower doses may suffice and doses as low as four 
Gy given in two fractions can be effective for palliation.
Surgery 
Surgery may be used as initial therapy for early stage 
MALT in locations not amenable to radiation, although 
with the low doses of radiation required, nearly all sites 
can be treated. While surgery is not the initial treat-
ment of choice for extranodal MALT, the pathologic 
diagnosis of MALT may become apparent only after a 
resection has taken place. If extranodal MALT lym-
phoma is diagnosed with an excisional biopsy and 
there is no evidence of residual disease, patients may 
be followed with close observation. However, if an initial 
surgical specimen demonstrates positive margins, ad-
juvant involved field RT is administered to avoid local 
recurrence. 
While MZL has a high response rate to chemotherapy, 
the benefit of adjuvant chemotherapy after radiotherapy 
has yet to be proven.
Extended (III-IV) disease 
Extended (III-IV) disease should be treated according 
to follicular NHL approaches.28 
The addition of anthracycline-based chemotherapy to 
RT in one RCT of 98 previously untreated patients 
with stage IE primary orbital MZL did not improve the 
results obtained following RT alone. A retrospective 
study of 38 patients with stage III/IV non-gastric MZL 
reported that the use of an anthracycline-containing 
chemotherapy regimen after RT improved the rate of 
CR but not PFS.
Unlike in gastric MALT, the benefit of antibiotic therapy 
for non-gastric MALT is unproven. In a prospective 
study of 77 patients with non-gastric MALT, evidence 
for infection with HP was present in 45%. However, in 
the sixteen HP-positive patients receiving eradication 
treatment before anti-lymphoma therapy, partial regres-
sion of the lymphoma was seen in only one patient. In 
relapsed/refractory MALT lymphoma, there is proof 
of principle for bortezomib (nine CR, five PR in 29 
evaluable patients in an open phase II trial).29
In ocular adnexal lymphoma, however, using PCR 
techniques, the C. Psittaci is detected (tumour tissue or 
conjonctival swab) in up to 89% of the cases. For this 
reason, doxycycline is recommended for CP irradiation 
and 65% of lymphoma regression is reported.25
Cutaneous MZL 
There are no clear treatment recommendations due to 
the lack of prospective data.
A localised nodule should be treated by RT (30Gy). In 
some cases with negative margins after resection, a 
watch-and-wait approach is recommended.  Radiation 
does not appear inferior to multiagent chemotherapy 
among patients with multiple lesions that can be in-
cluded in multiple radiation fields.30 Chemotherapy is 
reserved for extensive disease. 
An asymptomatic multifocal disease may be followed 
with close observation.
In symptomatic disease, radiation therapy of the symp-
tomatic sites can be useful. Rituximab is given com-
bined with an alkylating agent in symptomatic dissem-
inated disease but has no reimbursement in Belgium. 
Table 4. Splenic MZL. 
• Splenectomy alone
•  if contra-indications to surgery, single agent: 
- Rituximab: 375 mg/m²/wk x4 
- Chlorambucil: 16 mg/m²/d, 5 d/m x 6 mo or 6 mg/m²/d x 6 mo  
- Cyclophosphamide: 10 mg/m²/d x 6-12 mo 
- Fludarabine: 30 mg/m²/mo x 6 mo 
•   If associated with HCV 
- pegIFN-α2b (1.0 µg per kg weekly) 
- plus ribavirin (1000 – 1200 mg/d) 
•  Presence of adverse prognostic factors (high LDH  or B symp-
toms or presence of large cells (20% to 50%) at spleen  
histology or abdominal lymph nodes ) 
- R-CHOP every 3 wks for 6-8 cycles 
- R-FC every 4 wks for 6 cycles 
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Response evaluation and follow-up
Histological evaluation of repeated biopsies remains an 
essential follow-up procedure for intestinal lymphomas. 
The interpretation of a lymphoid infiltrate in post-treat-
ment non-gastric biopsies can be very difficult and 
there are no uniform criteria for the definition of histo-
logical remission. In the case of persistent but stable 
residual disease or histological relapse (without distant 
dissemination and/or gross endoscopic tumour) a 
watch-and-wait policy appears to be safe. 
In all other cases, long-term careful examination of 
extranodal organs (MALT) and systemic (blood cells 
counts, adequate radiological or ultrasound examina-




Nodal MZL represent 1% of all NHL and 10% of MZL. 
They present primary nodal involvement in the absence 
of any extra-nodal site with the exception of bone mar-
row,  with or without circulating cells (monocytoid B 
cells) but often produce a monoclonal immunoglobulin 
(IgM > IgG). Median age at diagnosis is 50 years old. 
The disease is often asymptomatic but in some patients, 
behaviour of the disease is more aggressive.31
Diagnosis
Diagnosis is based on the histopathological evaluation 
of a lymph node biopsy or on the cytomorphological 
analysis of circulating or bone marrow lymphoma cells. 
Bone marrow is involved in up to 70% of cases. 
No specific cytogenetic abnormalities have been asso-
ciated with nodal MZL.32
When a monoclonal B lymphocytosis is present in 
peripheral blood, other malignant hemopathies such 
as chronic lymphocytic leukaemia (CLL), hairy cell 
leukaemia (HCL), prolymphocytic leukaemia (PLL), 
follicular lymphoma (FNHL) or mantle cell lymphoma 
(MCL) should be excluded by phenotypic and genetic 








•  Lab test: CBC with diff and phenotype, biology 
with LDH, uric acid, ESR, proteins and electropho-
resis, ANA, RF, serologies (HCV, HBV, HIV), β2-
microglobulin
Table 5. Level of evidence (Infectious Diseases Society of American-United States Public Health 
Service Grading System).
I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses  
of well-conducted randomised trials without heterogeneity
II Small randomised trials of large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such 
trials or of trials demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grade for recommendation
A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc.), optional
D Moderate evidence against efficacy or for adverse outcome, generally not recommended
E Strong evidence against efficacy or for adverse outcome, never recommended






Staging and risk assessment
The initial staging procedures should include a lymph 
node biopsy followed by a work up to evaluate the 
extent of the disease and co-morbidities.
The value of positron emission tomography (PET) scan 
is controversial and is not routinely used unless histo-
logical transformation is suspected. 
Staging is done according to Ann Arbor. 
Treatment plan
There is no general consensus regarding the treatment 
of nodal MZL. Until more data are available patients 
are treated like those with indolent lymphomas.
Treatment of symptomatic patients with rituximab 
(either alone or in combination with chemotherapy) 
has shown remarkable responses.33
In asymptomatic cases, watchful waiting is recommend-
ed, while active anticancer treatment should be reserved 
for persistently symptomatic or progressive disease.
Only a few compounds and regimens have been tested 
specifically in MZL. Oral alkylating agents (either cyclo-
phosphamide or Chl) or purine analogues (fludarabine, 
cladribine) can result in a high rate of disease control. 
The activity of the anti-CD20 monoclonal antibody 
rituximab has also been shown in phase II studies and 
its efficacy in combination with Chl or purine analogs 
or bendamustine is now demonstrated: OR and CR 
reach 97 and 60% respectively.2,34,35 In a recent multi-
centre phase II trial presented at the ASH meeting, 
Bendamustine and rituximab as first line treatment 
resulted in 98% of CR and 85% of the patients only 
required four cycles.36 Anthracycline-containing regi-
mens are usually not necessary and should be reserved 
for the few patients with a high tumour burden.
Benda R as first-line treatment for patients with indo-
lent lymphomas was shown to be equal to R-CHOP 
with a better tolerance and a benefit in PFS.36
Lymphoma with diffuse large cell infiltration should be 




Splenic MZL is a unique entity (<1% NHL, <10% of 
MZL) of low-grade lymphoma infiltrating spleen, bone 
marrow and peripheral blood. Peripheral lymph nodes 
are not typically involved. Median age is 70 years old 
with a female predominance. 
Diagnosis
The most common presenting symptoms of splenic 
MZL are non specific abdominal complaints that often 
lead to abdominal ultrasound or CT, usually revealing 
splenomegaly or a routine blood cell count revealing 
circulating monoclonal B lymphocytes in an healthy 
patient.32 This lymphoma has been reported in patients 
with hepatitis C virus infection. Regression of the spleen 
was observed after eradication of the HCV (fourteen 
out of eighteen patients clearing hepC under interferon 
went into CR).37,38 This represents a subset of splenic 
MZL associated with chronic hepatitis C and mixed 
cryoglobulinemia. Many cases of splenic MZL are not 
hepatitis C driven. Approximately 40% of SMZL are 
associated with deletion of chromosome 7q32. Trisomy 
three is frequently associated with SMZL.39 Ten to forty 
percent of the patients have a serum monoclonal protein. 
Other lymphomas presenting with splenomegaly and 
a monoclonal B lymphocytosis are splenic MZL with 
villous lymphocytes, chronic lymphocytic leukaemia, 
hairy cell leukaemia, prolymphocytic leukaemia, fol-
licular lymphoma in leukemic phase and mantle cell 
lymphoma. Morphology, immunophenotype and mo-









LDH, uric acid, ESR, protein and electrophoresis, 
IgM, A, β2-microglobulin (Coombs, cryoglobulins 
if + HCV, 10-15% autoimmune phenomena)
•	 HCV	(RT-PCR	if	+	serology),	HBV,	HIV	serology
•	 	BM	biopsy	with	phenotype	and	cytogenetic	data	(+	
FISH or PCR for chromosome 3 and 7 abnormalities)
•	 Chest	X-ray,	CT	Scan	or	MRI,	echography
•	 Pregnancy	test	(if	applicable)
Staging and risk assessment
Work up studies should exclude involvement of other 
lymph nodes or extranodal sites. The majority of patients 
demonstrate an indolent course with a median OS in 
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excess of ten years. Factors associated with a shorter 
survival are elevated LDH, low haemoglobin level, older 
age and high IPI.32 14q aberrations and TP53 deletions are 
also poor prognostic indicators.39  In 25-30% of SMZL, an 
aggressive behaviour is observed with a shorter survival.
Treatment plan (Table 4)
Treatment is limited to those patients with symptomatic 
splenomegaly (discomfort, cytopenia, coexisting hepa-
titis C infection). 
Excellent disease control can be achieved by splenecto-
my or immunotherapy (rituximab). Splenectomy usually 
corrects pancytopenia and can lead to the reduction of 
circulating lymphocytes. Although it is a partial response, 
this situation can be maintained for ten years.5 Treat-
ment with single agent rituximab can result in a reduc-
tion of splenomegaly and normalisation of absolute 
lymphocyte counts in >90 % of patients.40
A single institution retrospectively analysed 70 patients 
with SMZL, 43 of whom underwent treatment with 
rituximab alone (26 patients), chemotherapy alone (11 
patients), or rituximab plus chemotherapy (6 patients), 
reported excellent outcomes in patients treated with 
single agent rituximab. When compared with those 
who received chemotherapy alone, patients who received 
single agent rituximab had superior rates of OR (88% 
vs. 55%), three year OS (86% vs. 45%) and three year 
failure-free survival (86% vs. 45%). Outcomes in patients 
who received both rituximab and chemotherapy were 
similar to those seen for patients who received ritux-
imab alone.41,42
Although this retrospective, uncontrolled study pro-
vides exciting initial data on the use of rituximab in 
this population, caution must be used with co-existing 
hepatitis C infection. Those with HCV should be treated 
by antiviral therapy (Peg IFNα2b 1µg/kg/w and riba-
virin 1g/d) and not rituximab.37
There have been a few series reporting improved symp-
toms after splenic irradiation or embolisation when the 
patient is not chemosensitive and not a candidate for 
splenectomy.43,44 Bendamustine also produces durable 
responses with acceptable toxicity but is only reim-
bursed in rituximab refractory patients.36
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